Yeji

$NTLA

Intellia Therapeutics, Inc.

Runway:10 mo
NasdaqMarket cap: —CIK 0001652130

Upcoming catalysts

2 surfaced
NDA/BLA filedDate TBD~ low confidence
$NTLAIntellia Therapeutics, Inc.
“Rolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first half of 2027, if approved”
NDA/BLA filedDate TBD
$NTLAIntellia Therapeutics, Inc.
lonvoguran ziclumeran · hereditary angioedema (HAE)
“Intellia announced that it initiated a rolling biologics license application ("BLA") submission to the U.S. Food and Drug Administration to seek regulatory approval of lonvo-z for the treatment of HAE.”

Drug pipeline

lonvoguran ziclumeran
hereditary angioedema (HAE)
Arm 1: NTLA-5001
Acute Myeloid Leukemia
Biological NTLA-3001
Lung Disease
NTLA-2001
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Biological NTLA-2002
Hereditary Angioedema
NTLA-2002
Hereditary Angioedema
nexiguran ziclumeran
Neuromuscular Disease

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06262399——Enrolling By Invitation2040-04-01
NCT05697861——Recruiting2038-03-01
NCT06128629NTLA-2001Phase 3Recruiting2027-12-01
NCT06672237nexiguran ziclumeranPhase 3Recruiting2027-07-01
NCT06634420NTLA-2002Phase 3Active Not Recruiting2026-02-10
NCT04601051NTLA-2001Phase 1Completed2025-09-12
NCT06622668Biological NTLA-3001Phase 2Withdrawn2025-01-09
NCT05120830Biological NTLA-2002Phase 2Active Not Recruiting2024-04-04
NCT05066165Arm 1: NTLA-5001Phase 2Terminated2022-07-21

Recent catalysts

NDA/BLA filedMar 2, 2026· 96d ago
$NTLAIntellia Therapeutics, Inc.
nexiguran ziclumeran · Neuromuscular Disease
“On March 2, 2026, Intellia announced that the U.S. Food and Drug Administration ("FDA") has removed the clinical hold on the investigational new drug application ("IND") for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran ("nex-z") for patients with transthyretin ("ATTR") amyloidosis with cardiomyopathy ("ATTR-CM").”
FDA approvalMar 2, 2026· 96d ago
$NTLAIntellia Therapeutics, Inc.
nexiguran ziclumeran · Neuromuscular Disease
“On March 2, 2026, Intellia announced that the U.S. Food and Drug Administration ("FDA") has removed the clinical hold on the investigational new drug application ("IND") for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran ("nex-z") for patients with transthyretin ("ATTR") amyloidosis with cardiomyopathy ("ATTR-CM").”
FDA approvalJan 27, 2026· 130d ago
$NTLAIntellia Therapeutics, Inc.
nexiguran ziclumeran · Neuromuscular Disease
“On January 27, 2026, Intellia announced that the U.S. Food and Drug Administration ("FDA") has removed the clinical hold on the investigational new drug application ("IND") for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran ("nex-z") for patients with hereditary transthyretin ("ATTR") amyloidosis with polyneuropathy ("ATTRv-PN").”
NDA/BLA filedJan 27, 2026· 130d ago
$NTLAIntellia Therapeutics, Inc.
nexiguran ziclumeran · Neuromuscular Disease
“On January 27, 2026, Intellia announced that the U.S. Food and Drug Administration ("FDA") has removed the clinical hold on the investigational new drug application ("IND") for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran ("nex-z") for patients with hereditary transthyretin ("ATTR") amyloidosis with polyneuropathy ("ATTRv-PN").”